期刊
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
卷 33, 期 8, 页码 336-348出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/cbr.2018.2494
关键词
actinides; actinium-225; coordination chemistry; macrocyclic ligands; radiopharmaceuticals; targeted alpha therapy
类别
资金
- Weill Cornell Medical College Clinical and Translational Science Center
- NIH/NCATS [UL1TR00457]
The alpha-emitting radionuclide actinium-225 possesses nuclear properties that are highly promising for use in targeted alpha therapy (TAT), a therapeutic strategy that employs alpha particle emissions to destroy tumors. A key factor, however, that may hinder the clinical use of actinium-225 is the poor understanding of its coordination chemistry, which creates challenges for the development of suitable chelation strategies for this ion. In this article, we provide an overview of the known chemistry of actinium and a summary of the chelating agents that have been explored for use in actinium-225-based TAT. This overview provides a starting point for researchers in the field of TAT to gain an understanding of this valuable therapeutic radionuclide.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据